Greenwich Lifesciences Inc (GLSI)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
NeutralGeprüft am 13.07.2026 gegen den Geschäftsbericht (10-K) für 2025 (eingereicht 01.06.2026) und die vier jüngsten Quartalsberichte (10-Q, zuletzt zum 31.03.2026, eingereicht 04.06.2026). In den ausgewerteten SEC-Filings von Greenwich LifeSciences findet sich kein wesentlicher KI-Bezug: keine Erwähnung von „artificial intelligence“, „machine learning“, „generative“ oder „large language model“ als Produkt, Werkzeug oder Geschäftsrisiko. Die scheinbaren Volltext-Treffer sind ausschließlich falsch-positive Substrings in medizinischen Fachbegriffen („HIV/AIDS“, „neurodegenerative“). Greenwich ist ein klinisches Biopharma-Unternehmen, dessen gesamter Bericht sich um die peptidbasierte Brustkrebs-Immuntherapie GLSI-100 (GP2 + GM-CSF) und die Phase-3-Studie Flamingo-01 dreht — KI spielt weder als Umsatzquelle noch im operativen Betrieb noch als eigenständiges Geschäftsrisiko eine Rolle. Nach dem Kriterienkatalog bleibt es damit bei „neutral“ (dokumentierter Negativ-Befund).
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-Q 2026-06-04 · 10-Q 2025-11-14 · 10-Q 2025-08-14 · 10-Q 2025-05-20 · 10-K 2026-06-01 · 10-K 2025-04-15
Rated on July 13, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.55 | – | 0 | – | – | -2 | -2 |
| 2025: Q1 | -0.19 | – | 0 | -20.00 | -68,625.00 | -2 | -2 |
| 2025: Q2 | -0.27 | – | 0 | – | – | -2 | -2 |
| 2025: Q3 | -0.28 | – | 0 | – | – | -3 | -3 |
| 2025: Q4 | -0.54 | – | 0 | – | – | -3 | -3 |
| 2026: Q1 | -0.39 | – | 0 | 0.00 | -141,425.00 | -5 | -5 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Greenwich LifeSciences, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt neuartige Krebsimmuntherapien gegen Brustkrebs und andere HER2/neu-exprimierende Krebsarten in den USA.
| Employees | 4 |
|---|---|
| Headquarters | Stafford, TX |
| Website | greenwichlifesciences.com |
| IPO Date | 25. Sep 2020 |
| Next Earnings | 13. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Snehal S. Patel | CEO, CFO & Director | 1964 |
| Eric Rothe | Founder & Independent Director | 1975 |
| Frank Joseph Daugherty M.D. | Chief Medical Officer & Director | 1951 |
| Jaye L. Thompson Ph.D. | Vice President Clinical & Regulatory Affairs | 1966 |
| Christine T. Fischette Ph.D. | VP of Business Development | 1951 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.